DOTA PET Segmentation: Precision TMTV for neuroendocrine tumors
Standardize the assessment of neuroendocrine tumors with AI-driven volumetric quantification and tracer-specific algorithms.
Enhancing Theranostics with Automated TMTV DOTA
"In the management of neuroendocrine tumors, the transition toward personalized peptide receptor radionuclide therapy requires absolute precision in tumor burden assessment."
In the management of neuroendocrine tumors (NETs), the transition toward personalized peptide receptor radionuclide therapy (PRRT) requires absolute precision in tumor burden assessment. Pixilib provides advanced algorithms for Neuroendocrine tumor segmentation, enabling the automated extraction of the TMTV DOTA (Total Metabolic Tumor Volume on DOTATOC/DOTATATE PET).
By integrating the uptake across all metastatic sites into a single volumetric metric, our platform provides researchers with a robust tool to predict patient prognosis and evaluate therapy response.
Advanced AI for Neuroendocrine Tumor Segmentation
Three complementary modules — tracer-specific detection, FDG/DOTA mismatch quantification, and human-validated review — built around the realities of NET research.
Tracer-Specific Algorithms for SSTR Imaging
Pixilib's AI engines are specifically trained to handle the unique biodistribution of somatostatin receptor (SSTR) tracers. Our Neuroendocrine tumor segmentation tool effectively:
- Identifies metastatic foci detecting lesions in common sites such as the liver, lymph nodes and bones
- Filters physiological uptake automatically accounting for normal tracer accumulation in the spleen, kidneys and pituitary gland
- Calculates TMTV DOTA with human-in-the-loop validated total volume
FDG and DOTA mismatch quantification
Using both FDG and DOTA segmentation AI algorithms, we are able to calculate the tumor mismatch between the two tracers and thus depict and quantify tumor differentiation.
This mismatch quantification can be used in many research projects and for patient selection for vectorized internal therapy.
Medical Validation: Human in the Loop
In clinical research, "black box" AI is not an option. Our "Human in the loop" approach ensures that the TMTV DOTA calculation remains under expert medical supervision, guaranteeing the highest data quality for your clinical trial endpoints.
Why Use GaelO for Your NET Research Projects?
From standardized PRRT monitoring to multicenter harmonization and downstream radiomics — three reasons to anchor your NET research in AI-validated tumor burden.
Standardized PRRT Monitoring
Follow the evolution of the TMTV DOTA throughout the course of radioligand therapy with high reproducibility.
Multicenter Harmonization
Neutralize the variability between different PET/CT scanners and reconstruction methods across global sites.
Ready for Advanced Analytics
Every Neuroendocrine tumor segmentation generates high-fidelity masks ready for radiomics extraction and statistical modeling.
A unified infrastructure for medical imaging research
From clinical trial centralization to research PACS and AI segmentation — three complementary products covering the full lifecycle of medical imaging in clinical research.
GaelO
Collection and centralized reading of clinical trials. From DICOM upload to Blind Independent Central Review with disease-specific criteria — GDPR/HIPAA compliant, fully auditable.
Discover GaelO
GaelO Flow
Research PACS for retrospective and Real World Evidence studies. Orchestrate medical imaging data: query/retrieve, batch de-identification, AI inference pipelines and seamless export.
Discover GaelO Flow
AI Segmentation Algorithms
FDG, PSMA, DOTATOC. Automated PET segmentation to extract Total Metabolic Tumor Volume (TMTV) human-in-the-loop, 100% medically validated, regulatory-ready.
Explore algorithms